Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

This article was originally published in The Gray Sheet

Executive Summary

The first company to enter the drug-eluting stent market will now be the first to depart.

You may also be interested in...

Medtronic Starts Next-Gen Drug-Eluting Stent Trials

The company is initially targeting very small vessels in a new pivotal study for its Resolute Onyx zotarolimus-eluting stent. Medtronic is separately launching a study of its novel "drug-filled" stent platform.

Cardinal Health Builds On Generic Device Strategy With Cordis Deal

The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.

News In Brief

NICE changes name, leader, and expands mission to social care. Cordis wins Cypher patent case on appeal. More news in brief.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts